<DOC>
	<DOCNO>NCT01442155</DOCNO>
	<brief_summary>This observational study evaluate efficacy safety capecitabine combination oxaliplatin adjuvant setting participant Stage III colon cancer . Data collect participant 36 month disease recurrence .</brief_summary>
	<brief_title>An Observational Study Adjuvant Treatment With Capecitabine ( Xeloda ) Combination With Oxaliplatin Participants With Stage III Colon Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Colonic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>Adult participant , &gt; /= 18 year age Treatment line currently approve indication Summary Product Characteristics Contraindications accord current Summary Product Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Colorectal cancer</keyword>
	<keyword>Adjuvant setting</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Oxaliplatin</keyword>
</DOC>